By Kamal Choudhury and Christy Santhosh
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Kura Oncology and Japanese partner Kyowa Kirin's once-daily pill, Komzifti, to treat a rare form of blood cancer that has returned or stopped responding to treatment.
The drug is approved for acute myeloid leukemia patients with an NPM1 mutation, a genetic change found in about 30% of cases.
Acute myeloid leukemia is an aggressive cancer of the blood and bone marrow.
Kura said the drug will be available within the next few business days at a price of $48,500 for a one-month supply.
With the approval, Kura's drug now competes with Syndax Pharmaceuticals' Revuforj, which was approved for the same indication by the FDA last month.
Komzifti’s approval comes with a boxed warning for differentiation syndrome and an additional warning for QTc interval prolongation, a delay in the heart’s electrical recovery after a beat, and potential harm to unborn babies.
A boxed warning is the U.S. Food and Drug Administration’s strongest alert for serious or life-threatening risks and appears prominently on a drug’s label to warn doctors and patients.
Revuforj carries a boxed warning for QTc interval prolongation, giving Kura “a significant competitive advantage,” according to Wedbush analysts.
Kura's Chief Medical Officer Mollie Leoni said the risk of QTc prolongation with Komzifti is low, adding it is “extraordinarily unlikely” to lead to a boxed warning.
The company said it is in dialogue with the FDA about potential steps post-approval that could help refine the labeling.
Under the terms of its collaboration with Kyowa, Kura is responsible for manufacturing Komzifti and will lead commercialization in the United States, while Kyowa handles commercial strategy and development outside the U.S.
Analysts, on average, expect Komzifti to have annual sales of $1.32 billion by 2031, according to LSEG data.
(Reporting by Kamal Choudhury and Christy Santhosh in Bengaluru; Editing by Shailesh Kuber and Tasim Zahid)
LATEST POSTS
- 1
PFAS in pregnant women’s drinking water puts their babies at higher risk, study finds - 2Figure out how to Put resources into Lab Precious stones: A Novice's Aide
- 3James Webb Space Telescope watches 'Jekyll and Hyde' galaxy shapeshift into a cosmic monster
- 4Revealing the Specialty of Food Matching: Improving Culinary Encounters
- 5Instructions to Boost Your True capacity with a Brain research Degree
- Share your pick for the riding area that characterizes your surf undertakings!
- The Secret Side of Italy: 12 Underrated Destinations Locals Don’t Want Tourists to Find
- College students are now slightly less likely to experience severe depression, research shows – but the mental health crisis is far from over
- One of the best meteor showers of the year peaks at the worst possible time this week
- Ads promising cosmetic surgery patients a ‘dream body’ with minimal risk get little scrutiny
- Watch interstellar comet 3I/ATLAS make its closest approach to Earth in free livestream on Dec. 18
- Equality requires universal draft, participation in economy and workforce, MK Liberman says
- A single shot of HPV vaccine may be enough to fight cervical cancer, study finds
- Ariana Grande and Jonathan Bailey will reunite for 'Sunday in the Park With George'
